# Erectile Dysfunction May Predispose Older Men to Multiple Types of Substance Abuse > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/erectile-dysfunction-may-predispose-older-men-to-multiple-types-of-substance-abuse/ > **Published:** 2026-05-20T10:37:14-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:54:39-04:00 > **Clinical Summary:** Erectile dysfunction may signal higher substance abuse risk in older men. Learn why ED screening matters for sedative and cannabis use. --- ✦ New CED Clinical Relevance #35 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. AgingMental HealthResearchSafetyAnxietyNeurologyPain Why This Matters Clinicians managing erectile dysfunction in older men should screen for concurrent substance abuse risk, as ED appears to be a significant predictor of sedative and other [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/) in this population. Understanding this association allows providers to implement preventive interventions and coordinate care across urology, psychiatry, and primary care to address both conditions. Patients with ED may benefit from discussing substance use history and risk factors during ED consultations, enabling earlier identification and treatment of emerging addiction before complications develop. Clinical Summary This cross-sectional study identified erectile dysfunction as a significant risk factor for substance abuse across multiple drug classes in older men, with the strongest associations observed for sedatives and opioids. The findings suggest that ED may serve as a marker for underlying medical complexity, psychological distress, or both, which predispose elderly men to misuse of prescription medications and other substances. The clinical significance lies in recognizing that older patients presenting with ED warrant careful substance use screening and assessment for depression or anxiety, conditions that commonly co-occur with sexual dysfunction. Additionally, clinicians should consider whether substance use itself may be contributing to or exacerbating erectile dysfunction, creating a bidirectional relationship that complicates treatment. Since cannabis is increasingly used by older adults for various conditions, including those with ED, clinicians should specifically explore [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns in this population and remain alert to potential polysubstance use patterns. For clinicians managing ED in older men, routine substance use screening and integrated mental health assessment may help identify and prevent harmful medication misuse before it develops. Dr. Caplan’s Take “What this research highlights is that we need to screen for substance use patterns in our older male patients presenting with ED, because the same vascular and neurological dysfunction driving erectile problems often creates vulnerability to self-medication with cannabis, alcohol, or sedatives, and we’re not adequately addressing the root causes before patients develop dependencies.” Clinical Perspective This observational study suggesting a link between erectile dysfunction and substance abuse in older men warrants careful clinical interpretation, as the cross-sectional design cannot establish causation and multiple confounders—including depression, cardiovascular disease, and polypharmacy—plausibly explain both conditions. The association with sedative-hypnotics is particularly relevant for cannabis-using patients, since both classes of substances carry risks of dependence and potential drug interactions that are often underappreciated in aging populations with multiple comorbidities. Clinicians should recognize that erectile dysfunction frequently signals underlying vascular or psychological distress that may drive patients toward self-medication strategies, including [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), rather than viewing substance use as a primary driver of sexual dysfunction. When evaluating older men with either ED or concerning substance use patterns, a thorough exploration of mood, vascular health, medication regimens, and psychosocial stressors—rather than categorical assumptions—can 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/medical-illness/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Erectile%20Dysfunction%20May%20Predispose%20Older%20Men%20to%20Multiple%20Types%20of%20Substance%20Abuse%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55838)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55838)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Erectile%20Dysfunction%20May%20Predispose%20Older%20Men%20to%20Multiple%20Types%20of%20Substance%20Abuse%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55838)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [In the Mix: 10 More Articles — May 19, 2026](https://cedclinic.com/cannabis-clinical-updates-may-2026/) 📰 Source: [https://www.medpagetoday.com/meetingcoverage/aua/121325](https://www.medpagetoday.com/meetingcoverage/aua/121325) Further Reading Cannabis Policy Wire[Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) CED Clinic Blog[Fear of recurrence, secondary cancers, and health problems in long-term survivors of childhood cancer: Findings from a Canadian cohort.](https://cedclinic.com/fear-of-recurrence-secondary-cancers-and-health-problems-in-long-term-survi/) CED Clinic Blog[Associations of cannabis use, other substances, and lifestyle choices on anxiety in medical cannabis patients across 45 days.](https://cedclinic.com/associations-of-cannabis-use-other-substances-and-lifestyle-choices-on-anxi/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).